FDA
-
-
-
-
-
-
-
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
-
-
-
-
-
-
-
Denali Therapeutics gains FDA approval for Hunter syndrome drug AVLAYAH
-
-
-
-
-
-
-
Denali Therapeutics to present data on enzyme therapies at medical conference
-
-
-
-
-
-
-
Denali's Hunter syndrome drug shows promise in published study
-
-
-
-
-
-
-
Denali Therapeutics names new board member, chief medical officer
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
-
-
-
-
-
-
-
Denali Therapeutics (DNLI) Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on
-
326,554 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

